All trials are not equal, even those conducted by the NCI. It’s all about design, according to leading lung cancer specialist.
20% fewer lung cancer deaths seen among those who were screened with low-dose spiral CT than with chest X-ray
Studies have shown that underutilization of hospice care increases end-of-life costs; more aggressive use of hospice could lead to significant savings and better care. Medicare seems to understand that promoting hospice care is not a "Death Panel."
Despite efforts by the manufacturer to reduce the cost of Avastin, the clinical effectiveness agency for England and Wales says that it will not recommend the drug for the first-line treatment of metastatic colorectal cancer.
ONCOLOGY board member Judd Moul, MD, told the CancerNetwork blog that there will be several controversial pro-con debates featured at this year’s Society of Urologic Oncology (SUO) meeting, May 29th in San Francisco. Dr. Moul will moderate a pro-con debate about the effectiveness of PSA screening during a session titled, Prostate Cancer I – Screening: Lessons from the PLCO and ESRPC Randomized Trials. Stand by for exclusive interviews and podcasts…
Almost 3 years after a controversial FDA denial, Provenge was approved, making it the first autologous cellular immunotherapy for prostate cancer. One pressing question about Provenge is how much its maker, the biotech company, Dendreon, would charge for its newly approved drug.
Justifying the huge capital investment in proton beam therapy centers requires a strategic model, in other words, a high-volume disease, such as prostate cancer.